OPCH Stock Forecast & Price Target

Option Care Health Inc. demonstrated a strong financial performance, with gross margin dollar generation increasing by 6.3% in the most recent quarter and a significant acceleration in its chronic therapy business, which grew over 10%. The company also showcased robust cash flow generation and a commitment to returning value to shareholders, evidenced by a notable increase in stock repurchases totaling $95 million in the fourth quarter. Additionally, the enhancement of fiscal year 2025 financial guidance reflects optimism for sustained revenue growth and margin expansion, supported by the operational efficiencies of its ambulatory facilities.

The negative outlook on Option Care Health’s stock is primarily driven by concerns regarding operational efficiency, as there is a noted expectation for general and administrative expenses to decline only gradually over the upcoming quarters. Additionally, the significant reliance on a single customer, which accounted for 14% of the company’s revenue in 2023, raises alarms about the potential impact on profitability should that customer be lost. Furthermore, the anticipated gross profit headwinds associated with the Stelara item, estimated at $25 million to $35 million in the near term and an annual impact of $65 million to $70 million, coupled with limited gross margin expansion prospects, suggest challenges in achieving future earnings growth.